|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRRC1 |
Gene summary for PRRC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRRC1 | Gene ID | 133619 |
| Gene name | proline rich coiled-coil 1 | |
| Gene Alias | PRRC1 | |
| Cytomap | 5q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q96M27 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 133619 | PRRC1 | LZE4T | Human | Esophagus | ESCC | 2.44e-04 | 1.35e-01 | 0.0811 |
| 133619 | PRRC1 | LZE20T | Human | Esophagus | ESCC | 7.03e-07 | 2.24e-01 | 0.0662 |
| 133619 | PRRC1 | LZE24T | Human | Esophagus | ESCC | 6.04e-12 | 3.65e-01 | 0.0596 |
| 133619 | PRRC1 | P1T-E | Human | Esophagus | ESCC | 7.25e-04 | 2.46e-01 | 0.0875 |
| 133619 | PRRC1 | P2T-E | Human | Esophagus | ESCC | 1.19e-32 | 4.99e-01 | 0.1177 |
| 133619 | PRRC1 | P4T-E | Human | Esophagus | ESCC | 5.08e-22 | 4.77e-01 | 0.1323 |
| 133619 | PRRC1 | P5T-E | Human | Esophagus | ESCC | 2.68e-14 | 2.21e-01 | 0.1327 |
| 133619 | PRRC1 | P8T-E | Human | Esophagus | ESCC | 9.18e-15 | 2.59e-01 | 0.0889 |
| 133619 | PRRC1 | P9T-E | Human | Esophagus | ESCC | 4.70e-09 | 2.77e-01 | 0.1131 |
| 133619 | PRRC1 | P10T-E | Human | Esophagus | ESCC | 6.93e-19 | 3.26e-01 | 0.116 |
| 133619 | PRRC1 | P11T-E | Human | Esophagus | ESCC | 9.56e-13 | 5.52e-01 | 0.1426 |
| 133619 | PRRC1 | P12T-E | Human | Esophagus | ESCC | 4.39e-21 | 4.03e-01 | 0.1122 |
| 133619 | PRRC1 | P15T-E | Human | Esophagus | ESCC | 7.18e-16 | 3.67e-01 | 0.1149 |
| 133619 | PRRC1 | P16T-E | Human | Esophagus | ESCC | 4.99e-18 | 3.64e-01 | 0.1153 |
| 133619 | PRRC1 | P17T-E | Human | Esophagus | ESCC | 2.92e-05 | 4.67e-01 | 0.1278 |
| 133619 | PRRC1 | P19T-E | Human | Esophagus | ESCC | 1.65e-02 | 4.24e-01 | 0.1662 |
| 133619 | PRRC1 | P20T-E | Human | Esophagus | ESCC | 1.39e-15 | 3.12e-01 | 0.1124 |
| 133619 | PRRC1 | P21T-E | Human | Esophagus | ESCC | 1.27e-19 | 3.96e-01 | 0.1617 |
| 133619 | PRRC1 | P22T-E | Human | Esophagus | ESCC | 6.76e-20 | 3.87e-01 | 0.1236 |
| 133619 | PRRC1 | P23T-E | Human | Esophagus | ESCC | 5.79e-23 | 5.48e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:004586011 | Liver | Cirrhotic | positive regulation of protein kinase activity | 117/4634 | 386/18723 | 7.07e-03 | 3.41e-02 | 117 |
| GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:00321471 | Liver | HCC | activation of protein kinase activity | 72/7958 | 134/18723 | 5.61e-03 | 2.33e-02 | 72 |
| GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
| GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
| GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
| GO:004586025 | Skin | cSCC | positive regulation of protein kinase activity | 123/4864 | 386/18723 | 5.23e-03 | 2.64e-02 | 123 |
| GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
| GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
| GO:00321472 | Thyroid | PTC | activation of protein kinase activity | 60/5968 | 134/18723 | 1.15e-03 | 6.71e-03 | 60 |
| GO:004586026 | Thyroid | ATC | positive regulation of protein kinase activity | 185/6293 | 386/18723 | 3.00e-09 | 7.02e-08 | 185 |
| GO:003367427 | Thyroid | ATC | positive regulation of kinase activity | 212/6293 | 467/18723 | 5.89e-08 | 1.05e-06 | 212 |
| GO:003214711 | Thyroid | ATC | activation of protein kinase activity | 65/6293 | 134/18723 | 2.44e-04 | 1.57e-03 | 65 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRRC1 | SNV | Missense_Mutation | novel | c.826G>A | p.Ala276Thr | p.A276T | Q96M27 | protein_coding | tolerated(0.06) | possibly_damaging(0.558) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PRRC1 | SNV | Missense_Mutation | c.1268A>C | p.Gln423Pro | p.Q423P | Q96M27 | protein_coding | deleterious(0.01) | possibly_damaging(0.777) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRRC1 | SNV | Missense_Mutation | novel | c.421A>C | p.Ile141Leu | p.I141L | Q96M27 | protein_coding | tolerated(0.07) | probably_damaging(0.99) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRRC1 | SNV | Missense_Mutation | c.136N>A | p.Ser46Thr | p.S46T | Q96M27 | protein_coding | tolerated_low_confidence(0.32) | benign(0.275) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PRRC1 | SNV | Missense_Mutation | rs147277611 | c.431N>A | p.Gly144Glu | p.G144E | Q96M27 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRRC1 | SNV | Missense_Mutation | novel | c.116N>A | p.Ser39Tyr | p.S39Y | Q96M27 | protein_coding | tolerated_low_confidence(0.32) | possibly_damaging(0.533) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| PRRC1 | SNV | Missense_Mutation | novel | c.1033G>T | p.Asp345Tyr | p.D345Y | Q96M27 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A7WK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| PRRC1 | SNV | Missense_Mutation | c.157N>T | p.Pro53Ser | p.P53S | Q96M27 | protein_coding | tolerated_low_confidence(0.07) | benign(0.311) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRRC1 | SNV | Missense_Mutation | rs749131929 | c.710T>C | p.Val237Ala | p.V237A | Q96M27 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| PRRC1 | SNV | Missense_Mutation | novel | c.374N>A | p.Pro125His | p.P125H | Q96M27 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.694) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |